Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities

NEXT STORY
Basilea reports strong financial results for half-year 2020, progress in R&D portfolio and successful completion of strategic projects, despite COVID-19
PREV STORY
Burning Rock Reports Second Quarter 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Immunomedics to Present at Jefferies 2016 Global Healthcare Conference

MORRIS PLAINS, N.J., June 07, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today  announced ...

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech withdraws a patent application

FIT Biotech Oy                                                                                                            Company release 13.9.2018 klo 3:45 PM EET   FIT Biotech withdraws ...

author_avatar
NASDAQ Market News

New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

author_avatar
NASDAQ Market News